Sponsored

Imugene (ASX: IMU) gets US patent for oncolytic virotherapy CF33, shares jump

July 19, 2023 02:20 PM AEST | By Team Kalkine Media
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Imugene has secured a patent for its licenced oncolytic virotherapy in the United States.
  • Oncolytic virotherapy CF33 comprises CHECKVacc and VAXINIA.
  • The patent protects the composition and usage methodology of the oncolytic virotherapy to 2037.

Imugene Limited (ASX: IMU), an Australian clinical-stage immune-oncology company, has informed about receiving a notice of allowance from the USPTO (US Patent and Trademark Office). The latest development of securing a US patent extends protection to the company’s oncolytic virotherapy CF33. 

Oncolytic virotherapy CF33 comprises CHECKVacc (CF33-hNIS-antiPDL1) and VAXINIA (CF33-hNIS).

Share price performance of Imugene 

Following the update, the share price of Imugene jumped to AU$0.10 per share, 9.68% higher at the time of writing on 19 July 2022. The company has a market cap of over AU$597 million.

About the patent

The title of the patent is - “CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF”, and the inventors are Yuman Fong and Nanhai Chen from the City of Hope. The patent protects the composition and usage methodology of the oncolytic virotherapy to 2037.

About oncolytic virotherapy CF33

CF33 is a chimeric vaccinia poxvirus, invented by Professor Yuman Fong.

The design of oncolytic viruses (OVs) activates the immune system against cancer cells and selectively kills tumour cells. OVs have the potential to enhance clinical responses and survival, says the company.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.